2. Academic Validation
  3. Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study

Determination of nifeviroc, a novel CCR5 antagonist: application to a pharmacokinetic study

  • J Pharm Biomed Anal. 2011 Nov 1;56(3):637-40. doi: 10.1016/j.jpba.2011.06.027.
Wei Wu 1,  Dong Xie,  Zeneng Cheng,  Zhi Liu,  Liling Ran,  Zhenkun Gu,  Peng Yu
Affiliations

Affiliation

  • 1 School of Pharmaceutical Sciences, Central South University, Changsha 410013, China.
PMID: 21802236 DOI: 10.1016/j.jpba.2011.06.027
Abstract

Nifeviroc is a novel CCR5 Antagonist used for the treatment of HIV type-1 Infection. A LC-ESI-MS/MS method for the determination of nifeviroc in human plasma was developed and validated. The calibration curve (r(2)=0.9993) of nifeviroc was established at the range of 1.924-2935 μg L(-1). The intra- and inter-day precisions (RSD%) were all less than 7%, and the accuracies at three concentration levels were all within 100 ± 5%. This validated method was then successfully applied to a pharmacokinetic study in health Chinese volunteers.

Figures
Products